Innate Pharma S.A. Sponsored ADR IPHA
1.70
0.00
0.00%
as of 25 Sep
- Market cap
- $188.8M
- P/E
- 0.0×
Follow IPHA
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
9.81 | 9.81 | 9.81 | 196.94 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
P/Operating CF |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Sales |
0.00 | 0.00 | 0.00 | 0.00 | (1.04) | (1.10) | (0.94) | (0.61) | (0.58) | (0.14) |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | 3.33 | 1.05 | 0.75 | 1.02 | 0.97 | 0.24 |
EV/Operating CF |
0.00 | 0.00 | 0.00 | 0.00 | 8.97 | 0.39 | 0.50 | 0.85 | 1.04 | 0.13 |
EV/FCF |
0.00 | 0.00 | 0.00 | 0.00 | 7.31 | 0.38 | 0.49 | 0.83 | 1.01 | 0.13 |
Quick Ratio |
2.92 | 1.78 | 1.62 | 1.95 | 3.81 | 1.73 | 3.38 | 3.73 | 2.60 | 1.27 |
Current Ratio |
3.01 | 1.86 | 1.62 | 1.95 | 3.81 | 1.73 | 3.38 | 3.73 | 2.60 | 1.27 |
Net Debt/EBITDA |
(110.61) | 2.37 | (12.99) | 19.02 | 25.11 | 1.75 | 4.93 | 6.94 | 1.00 | 0.22 |
Debt/Assets |
1.39% | 0.00% | 1.00% | 4.66% | 6.21% | 16.54% | 20.33% | 21.66% | 27.91% | 35.99% |
Debt/Equity |
0.05 | 0.06 | 0.03 | 0.09 | 0.12 | 0.41 | 0.78 | 0.77 | 3.51 | (1.04) |
Asset Turnover |
0.20 | 0.27 | 0.42 | 0.20 | 0.20 | 0.09 | 0.23 | 0.32 | 0.14 | 0.11 |
Operating CF/Net income |
(2.93) | 0.97 | (10.67) | (1.68) | 0.81 | 1.11 | 0.33 | 4.30 | 0.14 | 1.07 |
Capex/Depreciation |
0.00 | 0.00 | (0.19) | (3.96) | (0.20) | (0.29) | (0.02) | (0.43) | (0.20) | (0.10) |
Interest Coverage |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| 13.70% | (60.02%) | 2.39% | (10.54%) | (34.67%) | (40.93%) | (66.48%) | (14.47%) | (162.88%) | 742.02% | |
| 4.41% | (39.34%) | 1.35% | (4.73%) | (18.26%) | (18.72%) | (22.86%) | (3.92%) | (33.51%) | (58.22%) | |
ROIC |
0.00% | 0.00% | 76.02% | (97.88%) | (165.62%) | (93.83%) | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
7.77% | (65.09%) | 2.29% | (16.29%) | (45.82%) | (77.04%) | (54.28%) | (6.60%) | (85.45%) | (341.10%) |
Average Days of Receivables |
166.09 | 168.72 | 590.95 | 79.71 | 113.02 | 272.17 | 242.68 | 328.97 | 90.19 | 502.61 |
Research and Development Expense of Revenue |
81.12% | 192.86% | 74.03% | 91.88% | 83.20% | 190.28% | 89.58% | 90.88% | 258.34% | 484.40% |
Selling, General and Administrative Expense of Revenue |
16.61% | 51.14% | 19.31% | 30.07% | 44.35% | 103.32% | 38.90% | 29.67% | 97.99% | 215.37% |
Intangible Assets out of Total Assets |
0.03 | 0.00 | 0.19 | 0.24 | 0.15 | 0.17 | 0.01 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 2.88% | 4.46% | 3.51% | 10.59% | 7.37% | 6.90% | 19.60% | 28.51% |
Graham Net Nets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
10.20% | 10.20% | 10.20% | 0.51% | (32.55%) | (38.67%) | (45.45%) | (42.89%) | (63.40%) | (66.66%) |
Free Cash Flow Yield |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Revenue per Share |
1.10 | 0.72 | 1.89 | 1.44 | 1.02 | 0.37 | 0.76 | 0.83 | 0.27 | 0.11 |
Operating CF per Share |
(0.72) | (1.04) | (0.65) | 0.58 | (0.75) | (0.87) | (0.25) | (0.44) | (0.09) | (0.67) |
Capex per Share |
0.00 | 0.00 | (0.03) | (1.09) | (0.16) | (0.02) | (0.01) | (0.03) | (0.01) | 0.00 |
Free Cash Flow per Share |
(0.72) | (1.04) | (0.68) | (0.51) | (0.91) | (0.89) | (0.27) | (0.47) | (0.10) | (0.67) |
Cash per Share |
3.86 | 2.57 | 3.37 | 3.66 | 2.19 | 1.78 | 1.34 | 1.24 | 1.08 | 0.43 |
Shareholders Equity per Share |
1.68 | 1.91 | 3.36 | 3.64 | 2.26 | 1.60 | 0.72 | 0.70 | 0.12 | (0.27) |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
1.68 | 1.91 | 3.36 | 3.64 | 2.26 | 1.60 | 0.72 | 0.70 | 0.12 | (0.27) |
Free Cash Flow |
(38.92) | (56.30) | (40.08) | (34.13) | (72.01) | (70.73) | (21.36) | (37.62) | (7.89) | (59.85) |
Working Capital |
161.72 | 76.64 | 145.15 | 129.68 | 146.17 | 69.06 | 103.77 | 117.29 | 57.09 | 11.38 |
Capital Expenditures |
(9.89) | (7.26) | (1.66) | (73.25) | (12.88) | (1.57) | (1.18) | (2.38) | (0.42) | (0.16) |
Net Current Asset Value |
36.49 | (38.01) | 42.12 | 60.10 | 25.14 | (25.79) | (14.63) | 17.01 | (17.84) | (42.67) |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
0.00 | 0.00 | 0.02 | 0.76 | 0.16 | 0.05 | 0.02 | 0.04 | 0.02 | 0.02 |
Net Profit Margin |
22.51% | (148.28%) | 3.25% | (24.19%) | (90.82%) | (213.78%) | (100.74%) | (12.28%) | (245.87%) | (546.11%) |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.36 | 0.41 | 0.72 | 1.42 | 4.86 | 0.45 | 5.32 | 0.81 | 0.39 | 0.32 |
Cash ROIC |
(16.01%) | (27.78%) | (12.60%) | 5.11% | (19.42%) | (25.28%) | (14.00%) | (21.10%) | (9.97%) | (162.34%) |
Accounts Receivable Turnover |
2.62 | 1.74 | 1.12 | 0.96 | 3.51 | 1.25 | 1.95 | 1.33 | 0.66 | 1.05 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
0.00 | — | — | — | — | — | — | — | — | — |
Average Receivables |
22.54 | 22.54 | 98.91 | 100.32 | 22.95 | 23.36 | 31.10 | 50.27 | 32.75 | 9.70 |
Average Payables |
20.24 | 20.24 | 66.15 | 81.84 | 44.59 | 33.77 | 27.92 | 20.23 | 17.87 | 17.17 |
Average Assets |
301.83 | 148.20 | 266.44 | 491.21 | 400.35 | 333.82 | 267.74 | 209.18 | 159.76 | 95.57 |
Average Common Equity |
97.13 | 97.13 | 150.54 | 220.51 | 210.84 | 152.64 | 92.08 | 56.61 | 32.87 | (7.50) |
Columns are period end dates